Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of cardiometabolic diseases, extending their therapeutic applications far beyond glycemic control in type 2 diabetes (T2D) and obesity. This editorial synthesizes key milestones, from the discovery of GLP...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12933-025-02608-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572040626831360 |
|---|---|
| author | Francisco Westermeier Enrique Z. Fisman |
| author_facet | Francisco Westermeier Enrique Z. Fisman |
| author_sort | Francisco Westermeier |
| collection | DOAJ |
| description | Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of cardiometabolic diseases, extending their therapeutic applications far beyond glycemic control in type 2 diabetes (T2D) and obesity. This editorial synthesizes key milestones, from the discovery of GLP-1 to recent clinical trials highlighting the pleiotropic effects of GLP-1RAs in addressing the interconnected spectrum of cardiometabolic conditions, with a focus on cardiovascular, renal, and hepatic benefits. In addition, as GLP-1RAs continue to reshape the management of cardiometabolic disease and global public health, we discuss future challenges to better elucidate their mechanisms of cardiometabolic protection and maximize their therapeutic potential. Graphical abstract |
| format | Article |
| id | doaj-art-fa92694878fc446cb61139eb51b0b8d8 |
| institution | Kabale University |
| issn | 1475-2840 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj-art-fa92694878fc446cb61139eb51b0b8d82025-02-02T12:07:24ZengBMCCardiovascular Diabetology1475-28402025-01-012411810.1186/s12933-025-02608-9Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challengesFrancisco Westermeier0Enrique Z. Fisman1Institute of Biomedical Science, Department of Health Studies, FH Joanneum University of Applied SciencesFaculty of Medicine, Tel Aviv UniversityAbstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of cardiometabolic diseases, extending their therapeutic applications far beyond glycemic control in type 2 diabetes (T2D) and obesity. This editorial synthesizes key milestones, from the discovery of GLP-1 to recent clinical trials highlighting the pleiotropic effects of GLP-1RAs in addressing the interconnected spectrum of cardiometabolic conditions, with a focus on cardiovascular, renal, and hepatic benefits. In addition, as GLP-1RAs continue to reshape the management of cardiometabolic disease and global public health, we discuss future challenges to better elucidate their mechanisms of cardiometabolic protection and maximize their therapeutic potential. Graphical abstracthttps://doi.org/10.1186/s12933-025-02608-9Glucagon-like peptide-1GLP-1Cardiometabolic diseasesType 2 diabetesObesityChronic kidney disease |
| spellingShingle | Francisco Westermeier Enrique Z. Fisman Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges Cardiovascular Diabetology Glucagon-like peptide-1 GLP-1 Cardiometabolic diseases Type 2 diabetes Obesity Chronic kidney disease |
| title | Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges |
| title_full | Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges |
| title_fullStr | Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges |
| title_full_unstemmed | Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges |
| title_short | Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges |
| title_sort | glucagon like peptide 1 glp 1 agonists and cardiometabolic protection historical development and future challenges |
| topic | Glucagon-like peptide-1 GLP-1 Cardiometabolic diseases Type 2 diabetes Obesity Chronic kidney disease |
| url | https://doi.org/10.1186/s12933-025-02608-9 |
| work_keys_str_mv | AT franciscowestermeier glucagonlikepeptide1glp1agonistsandcardiometabolicprotectionhistoricaldevelopmentandfuturechallenges AT enriquezfisman glucagonlikepeptide1glp1agonistsandcardiometabolicprotectionhistoricaldevelopmentandfuturechallenges |